Zai Lab Launches Hong Kong Secondary Listing - TC Read more about Zai Lab Launches Hong Kong Secondary Listing - TC
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China - TC Read more about Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China - TC
Zai Lab Announces Clinical Data to be Presented at ESMO Virtual Congress 2020 - TC Read more about Zai Lab Announces Clinical Data to be Presented at ESMO Virtual Congress 2020 - TC
Zai Lab Announces Upcoming Participation in September Conferences - TC Read more about Zai Lab Announces Upcoming Participation in September Conferences - TC
Zai Lab Appoints F. Ty Edmondson as Chief Legal Officer - TC Read more about Zai Lab Appoints F. Ty Edmondson as Chief Legal Officer - TC
Zai Lab Announces NDA for Ripretinib Granted Priority Review by China’s NMPA - TC Read more about Zai Lab Announces NDA for Ripretinib Granted Priority Review by China’s NMPA - TC
Zai Lab to Announce Financial Results for the Six Months Ended June 30, 2020 and Corporate Updates - TC Read more about Zai Lab to Announce Financial Results for the Six Months Ended June 30, 2020 and Corporate Updates - TC
Ripretinib Becomes the First Unregistered Drug in Mainland China Approved for the Named Patient Program Outside the Pilot Zone of Hainan Province - TC Read more about Ripretinib Becomes the First Unregistered Drug in Mainland China Approved for the Named Patient Program Outside the Pilot Zone of Hainan Province - TC
China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor - TC Read more about China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor - TC
Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China - TC Read more about Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China - TC